Amyloid-beta immunisation for Alzheimer's disease.

Abstract

Alzheimer's disease is the main cause of dementia in elderly people and is becoming an ever greater problem as societies worldwide age. Treatments that stop or at least effectively modify disease course do not yet exist. In Alzheimer's disease, the conversion of the amyloid-beta peptide (Abeta) from a physiological water-soluble monomeric form into neurotoxic oligomeric and fibrillar forms rich in stable beta-sheet conformations is an important event. The most toxic forms of Abeta are thought to be oligomers, and dimers might be the smallest neurotoxic species. Numerous immunological approaches that prevent the conversion of the normal precursor protein into pathological forms or that accelerate clearance are in development. More than ten new approaches to active and passive immunotherapy are under investigation in clinical trials with the aim of producing safe methods for immunological therapy and prevention. A delicate balance between immunological clearance of an endogenous protein with acquired toxic properties and the induction of an autoimmune reaction must be found.

DOI: 10.1016/S1474-4422(08)70170-4
0200400200920102011201220132014201520162017
Citations per Year

1,289 Citations

Semantic Scholar estimates that this publication has 1,289 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Wisniewski2008AmyloidbetaIF, title={Amyloid-beta immunisation for Alzheimer's disease.}, author={Thomas Wisniewski and Uwe Konietzko}, journal={The Lancet. Neurology}, year={2008}, volume={7 9}, pages={805-11} }